Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMPREVENCE: EVO100 for Chlamydia and Gonorrhea Prevention
NCT03107377Phase 3Completed
- Sponsor
- Evofem Biosciences, Inc.
- Start
- Nov 2017
- Primary completion
- Aug 2019
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Chlamydia trachomatis infection and gonorrhea comparing EVO100 with Placebo (2 arms). Primary endpoint: Proportion of subjects who experience urogenital Chlamydia trachomatis infection at 16 weeks. Started Nov 2017; status: completed.
02
Drugs
Phexxi
03
Conditions
Chlamydia trachomatis infectiongonorrhea
Beyond the preview
Go deeper on NCT03107377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03107377.